1. AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders. (12th June 2018) Authors: Crowley, J.; Papp, K.A.; Hong, C.-H.; Parno, J.; Mendelsohn, A.M.; Li, Q.; Cichanowitz, N.; La Rosa, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. (12th June 2018) Authors: Blauvelt, A.; Sofen, H.; Papp, K.; Gooderham, M.; Zhao, Y.; Lowry, S.; Mendelsohn, A.; Parno, J.; Li, Q.; Rosa, C.L.; Reich, K. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. (3rd August 2020) Authors: Menter, M.A.; Murakawa, G.J.; Glover, H.; Mendelsohn, A.M.; Parno, J.; Rozzo, S.J.; Davidson, D.; Gupta, A.K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: e803 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. (2nd January 2022) Authors: Gordon, K. B.; Reich, K.; Crowley, J. J.; Korman, N. J.; Murphy, F. T.; Poulin, Y.; Spelman, L.; Yamauchi, P. S.; Mendelsohn, A. M.; Parno, J.; Rozzo, S. J.; Ellis, C. N. Journal: Journal of dermatological treatment Issue: Volume 33:Number 1(2022) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of baseline dyskinesia on safety and efficacy of istradefylline, an A2A receptor antagonist, in Parkinson's disease: 8-study pooled analysis. (October 2020) Authors: Truong, D.; Hattori, N.; Isaacson, S.H.; Rascol, O.; Mori, A.; Toyama, K.; Parno, J.; Salzman, P.M.; Ristuccia, R.; Stocchi, F. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of istradefylline, an A2A receptor antagonist, when added to levodopa and other medications for Parkinson's disease (PD). (October 2020) Authors: Le Witt, P.; Hattori, N.; Mori, A.; Toyama, K.; Salzman, P.M.; Parno, J.; Ristuccia, R.; Isaacson, S.H. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis. (9th February 2020) Authors: Poulin, Y.; Ramon, M.; Rosoph, L.; Weisman, J.; Mendelsohn, A.M.; Parno, J.; Rozzo, S.J.; Lee, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 7(2020) Page Start: 1500 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Sea-ice production and air/ice/ocean/biogeochemistry interactions in the Ross Sea during the PIPERS 2017 autumn field campaign. Issue 82 (11th September 2020) Authors: Ackley, S. F.; Stammerjohn, S.; Maksym, T.; Smith, M.; Cassano, J.; Guest, P.; Tison, J.-L.; Delille, B.; Loose, B.; Sedwick, P.; DePace, L.; Roach, L.; Parno, J. Journal: Annals of glaciology Issue: Volume 61:Issue 82(2020) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials. (11th September 2019) Authors: Blauvelt, A.; Sofen, H.; Papp, K.; Gooderham, M.; Tyring, S.; Zhao, Y.; Lowry, S.; Mendelsohn, A.; Parno, J.; Reich, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 12(2019) Page Start: 2305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗